Injectable ALK-N001

Phase 2

ZZhejiang Anglikang Pharmaceutical Co., Ltd.

Injectable ALK-N001 is one of 11 therapeutic programs targeting Gastrointestinal Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Gastrointestinal TumorsNot yet recruiting

Gastrointestinal TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Gastrointestinal Tumors

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Phase 2

1 2

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 3

BL-M24D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 4

Injectable ALK-N001

ZZhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 2

1 5

BL-M09D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 6

BL-M02D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 7

GNC-077

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 8

BL-M08D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 9

Bl-Arc002

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 10

Lutetium BL-ARC001

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Gastrointestinal Tumors

NCT07826195

Clinical

Trials by Indication[1]

Gastrointestinal Tumors1 trial

An Open-label, Multicenter Phase IIa Study to Evaluate the Efficacy and Safety of Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

Not yet recruiting·ZZhejiang Anglikang Pharmaceutical Co., Ltd.·Phase 2·NCT07826195·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Injectable ALK-N001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Injectable ALK-N001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhejiang Anglikang Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: ZZhejiang Anglikang Pharmaceutical Co., Ltd.

Injectable ALK-N001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Gastrointestinal Tumors1 trial

References

Drug Info

Quick Facts

Related News